Compare PLSE & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | LMAT |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2015 | 2006 |
| Metric | PLSE | LMAT |
|---|---|---|
| Price | $27.44 | $103.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $22.00 | ★ $105.80 |
| AVG Volume (30 Days) | 344.9K | ★ 359.0K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | N/A | ★ 30.57 |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $249,602,000.00 |
| Revenue This Year | $840.00 | $14.21 |
| Revenue Next Year | $287.54 | $8.88 |
| P/E Ratio | ★ N/A | $155.44 |
| Revenue Growth | N/A | ★ 13.53 |
| 52 Week Low | $12.56 | $79.01 |
| 52 Week High | $31.00 | $118.01 |
| Indicator | PLSE | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 61.10 |
| Support Level | $23.94 | $82.65 |
| Resistance Level | $27.82 | $114.38 |
| Average True Range (ATR) | 1.72 | 3.19 |
| MACD | 0.02 | 1.67 |
| Stochastic Oscillator | 42.03 | 81.36 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.